Page last updated: 2024-11-01

nimodipine and Dementia

nimodipine has been researched along with Dementia in 13 studies

Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.

Dementia: An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.

Research Excerpts

ExcerptRelevanceReference
"The effects of galantamine (GAL) on quality of life (QoL) and cognitive speed, as well its effects combined with nimodipine (NIM) in Alzheimer disease (AD) with cerebrovascular disease (mixed dementia), have not been explored."9.19Effects of galantamine and galantamine combined with nimodipine on cognitive speed and quality of life in mixed dementia: a 24-week, randomized, placebo-controlled exploratory trial (the REMIX study). ( Barbosa, MT; Bottino, CM; Caramelli, P; Charchat-Fichman, H; Chaves, ML; Forlenza, OV; Laks, J; Lawson, FL; Machado, JC; Nitrini, R; Palmini, AL; Vale, Fde A, 2014)
"Forty patients aged 65-80 with minor-medium signs of brain aging were treated for 6 months with daily 90 mg doses of nimodipine."9.07[Brain aging and calcium antagonist drugs. A preliminary open study with nimodipine]. ( Albano, O; Cassiano, MA; Centonze, V; Cirillo, L; Di Bari, M; Massaro, C; Polito, BM; Russo, P, 1992)
" In a multicenter, placebo-controlled, double-blind clinical study in 178 elderly patients with cognitive decline, nimodipine, a calcium antagonist was found to be a therapeutically effective agent in the treatment of old age dementias."9.06Nimodipine in the treatment of old age dementias. ( Aguglia, E; Azzarelli, O; Balsano, F; Ban, TA; Caglieris, N; Capurso, A; Marigliano, V; Morey, L; Sterlicchio, M; Tomasi, NA, 1990)
"The effects of galantamine (GAL) on quality of life (QoL) and cognitive speed, as well its effects combined with nimodipine (NIM) in Alzheimer disease (AD) with cerebrovascular disease (mixed dementia), have not been explored."5.19Effects of galantamine and galantamine combined with nimodipine on cognitive speed and quality of life in mixed dementia: a 24-week, randomized, placebo-controlled exploratory trial (the REMIX study). ( Barbosa, MT; Bottino, CM; Caramelli, P; Charchat-Fichman, H; Chaves, ML; Forlenza, OV; Laks, J; Lawson, FL; Machado, JC; Nitrini, R; Palmini, AL; Vale, Fde A, 2014)
"Forty patients aged 65-80 with minor-medium signs of brain aging were treated for 6 months with daily 90 mg doses of nimodipine."5.07[Brain aging and calcium antagonist drugs. A preliminary open study with nimodipine]. ( Albano, O; Cassiano, MA; Centonze, V; Cirillo, L; Di Bari, M; Massaro, C; Polito, BM; Russo, P, 1992)
" In a multicenter, placebo-controlled, double-blind clinical study in 178 elderly patients with cognitive decline, nimodipine, a calcium antagonist was found to be a therapeutically effective agent in the treatment of old age dementias."5.06Nimodipine in the treatment of old age dementias. ( Aguglia, E; Azzarelli, O; Balsano, F; Ban, TA; Caglieris, N; Capurso, A; Marigliano, V; Morey, L; Sterlicchio, M; Tomasi, NA, 1990)
"The possibilities and limitations of treatment of dementia with nootropic agents are discussed."2.38[Therapy of dementing diseases: value of calcium antagonists]. ( Möller, HJ, 1993)

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's11 (84.62)18.2507
2000's1 (7.69)29.6817
2010's1 (7.69)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Caramelli, P1
Laks, J1
Palmini, AL1
Nitrini, R1
Chaves, ML1
Forlenza, OV1
Vale, Fde A1
Barbosa, MT1
Bottino, CM1
Machado, JC1
Charchat-Fichman, H1
Lawson, FL1
Eckert, A1
Fischhof, PK1
Fanelli, RJ1
McCarthy, RT1
Chisholm, J1
Zhang, JT1
Ganesan, R1
Standish, T1
Molloy, DW1
Darzins, P1
Orange, JB1
Möller, HJ1
Stoppe, G1
Sandholzer, H1
Staedt, J1
Winter, S1
Kiefer, J1
Rüther, E1
Ojer Tsakiridu, D1
Dosantos Hernández, JO1
Larrabe Medina, J1
Sánchez Casado, JI1
Sologuren Echenagusia, A1
Centonze, V1
Massaro, C1
Polito, BM1
Cassiano, MA1
Di Bari, M1
Russo, P1
Cirillo, L1
Albano, O1
Biersack, K1
Rosskopf, R1
Eckert, H1
Pasz, T1
Herrmann, WM1
Stephan, K1
Ban, TA1
Morey, L1
Aguglia, E1
Azzarelli, O1
Balsano, F1
Marigliano, V1
Caglieris, N1
Sterlicchio, M1
Capurso, A1
Tomasi, NA1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life[NCT00814658]Phase 422 participants (Actual)Interventional2008-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Reaction Time for Face Recognition Test at Baseline, Week 8, and Week 24

The face recognition test is a computerized attention test in which ten unfamiliar faces were presented simultaneously on the computer screen for ten seconds to be remembered. After that, a single face was shown and the patient had to press the button one if he/she remembered or, otherwise, button five. It consisted of a random presentation of ten pre-exposed faces and ten new faces as distracters. The reaction time, assessed per patient, was averaged at each time point for each patient e.g., at baseline, Weeks 8 and 24. This test is part of the Computerized Neuropsychological Test Battery. (NCT00814658)
Timeframe: Baseline, Week 8, Week 24

Interventionmilliseconds (Mean)
Galantamine + Nimodipine (Baseline)3124.00
Galantamine + Placebo (Baseline)2684.45
Galantamine + Nimodipine (Week 8)2262.50
Galantamine + Placebo (Week 8)2734.25
Galantamine + Nimodipine (Week 24)2357.80
Galantamine + Placebo (Week 24)3099.38

Reaction Time for Simple Reaction Time Test at Baseline, Week 8, and Week 24

The Simple Reaction Time is a computerized attention test that evaluates the patient's reaction time. The number one was presented in the center of the computer screen and the patient had to press this number in the response box as quickly as possible. The reaction time, assessed 100 times per patient, was averaged at each time point for each patient e.g., at baseline, Week 8 and Week 24. The patient's finger was put over button one before the test begun. This test is part of the Computerized Neuropsychological Test Battery (CNTB). (NCT00814658)
Timeframe: Baseline, Week 8, Week 24

Interventionmilliseconds (Mean)
Galantamine + Nimodipine (Baseline)1024.06
Galantamine + Placebo (Baseline)729.18
Galantamine + Nimodipine (Week 8)466.60
Galantamine + Placebo (Week 8)671.33
Galantamine + Nimodipine (Week 24)467.60
Galantamine + Placebo (Week 24)584.44

Reaction Time for Two-choice Reaction Time Test at Baseline, Week 8, and Week 24

The Two-choice reaction time test is a computerized attention test in which the numbers one or five were presented in the center of the computer screen in a random order. The patient had to press the correspondent button in the response box as quickly as possible. The patient's right finger was put over the button five and the left finger over button one before the test begun. The reaction time, assessed 100 times per patient, was averaged at each time point for each patient e.g., at baseline, Week 8 and Week 24.This test is part of the Computerized Neuropsychological Test Battery (CNTB). (NCT00814658)
Timeframe: Baseline, Week 8, Week 24

Interventionmilliseconds (Mean)
Galantamine + Nimodipine (Baseline)1919.72
Galantamine + Placebo (Baseline)1096.75
Galantamine + Nimodipine (Week 8)852.70
Galantamine + Placebo (Week 8)1187.78
Galantamine + Nimodipine (Week 24)727.60
Galantamine + Placebo (Week 24)1116.25

Reaction Time for Word Recognition and Learning Test at Baseline, Week 8, and Week 24

The reaction time for word recognition and learning test is a computerized attention test that evaluates the patient's reaction time. This test is similar to the Face Recognition test procedure using Words. The recognition procedure was repeated three times to evaluate a learning effect. The reaction time, assessed per patient, was averaged at each time point for each patient e.g., at baseline, Week 8 and Week 24. This test is part of the Computerized Neuropsychological Test Battery (CNTB). (NCT00814658)
Timeframe: Baseline, Week 8, Week 24

Interventionmilliseconds (Mean)
Galantamine + Nimodipine (Baseline)2022.17
Galantamine + Placebo (Baseline)2978.77
Galantamine + Nimodipine (Week 8)1966.40
Galantamine + Placebo (Week 8)2379.83
Galantamine + Nimodipine (Week 24)1722.00
Galantamine + Placebo (Week 24)3038.81

The Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) at Baseline, Week 8, and Week 24

The ADAS-Cog is a psychometric instrument that evaluates memory, attention, reasoning, language, orientation and praxis using an 11-point Assessment Scale. It has a minimum score of 0 and a maximum severity score of 70, and a higher score indicates more impairment. (NCT00814658)
Timeframe: Baseline, Week 8, Week 24

Interventionscores on a scale (Mean)
Galantamine + Nimodipine (Baseline)30.40
Galantamine + Placebo (Baseline)28.20
Galantamine + Nimodipine (Week 8)25.10
Galantamine + Placebo (Week 8)31.03
Galantamine + Nimodipine (Week 24)25.02
Galantamine + Placebo (Week 24)27.70

The Neuropsychiatric Inventory (NPI) at Baseline, Week 8, and Week 24

The NPI evaluates 12 neuropsychiatric domains: delusions, hallucinations, dysphoria, anxiety, aggression, euphoria, dis-inhibition, irritability/lability, apathy, aberrant motor activity, eating disorders, and night-time behavior disturbances. For present domains, the severity and frequency of the behavior are determined. Frequency is rated 1 (rarely) to 4 (very often) and Severity is scored 1 (mild) to 3 (severe). The product scores vary from 1 (mild and rarely) to 12 (very often and severe). Total scores vary from 0 (no present domain) to 144 (all domains are present, are often and severe). (NCT00814658)
Timeframe: Baseline, Week 8, Week 24

Interventionscores on a scale (Mean)
Galantamine + Nimodipine (Baseline)24.0
Galantamine + Placebo (Baseline)26.92
Galantamine + Nimodipine (Week 8)20.20
Galantamine + Placebo (Week 8)22.11
Galantamine + Nimodipine (Week 24)15.00
Galantamine + Placebo (Week 24)19.75

The Quality of Life Assessment for Caregivers of Patients With Alzheimer's Disease (QoL- AD) Total Scores at Baseline, Week 8, Week 24

The Quality of Life assessment scale for caregivers of patients with Alzheimer's disease (QoL-AD) is a 13-item scale with four possible scores for each question (score 1: poor and score 4: excellent). It evaluates the caregivers own perceived quality of life. Total score ranges from 13 to 52. Higher scores represent a better outcome. (NCT00814658)
Timeframe: Baseline, Week 8, Week 24

Interventionscores on a scale (Mean)
Galantamine + Nimodipine (Baseline)34.00
Galantamine + Placebo (Baseline)36.50
Galantamine + Nimodipine (Week 8)32.00
Galantamine + Placebo (Week 8)33.56
Galantamine + Nimodipine (Week 24)36.60
Galantamine + Placebo (Week 24)34.88

The Quality of Life Assessment for Patients With Alzheimer's Disease (QoL- AD) Total Scores at Baseline, Week 8, Week 24

The Quality of Life assessment scale for patients with Alzheimer's disease (QoL-AD) is a 13-item scale with four possible scores for each question (score 1: poor and score 4: excellent). Total score ranges from 13 to 52. Higher scores represent a better outcome. (NCT00814658)
Timeframe: Baseline, Week 8, Week 24

Interventionscores on a scale (Mean)
Galantamine + Nimodipine (Baseline)33.56
Galantamine + Placebo (Baseline)32.67
Galantamine + Nimodipine (Week 8)35.60
Galantamine + Placebo (Week 8)33.11
Galantamine + Nimodipine (Week 24)36.60
Galantamine + Placebo (Week 24)33.86

The Quality of Life Assessment for Patients With Alzheimer's Disease (QoL- AD) Total Scores, Based on the Caregiver's Opinion, at Baseline, Week 8, Week 24

The Quality of Life assessment scale for patients with Alzheimer's disease (QoL-AD), according to the opinion of the caregiver is a 13-item scale with four possible scores for each question (score 1: poor and score 4: excellent). It evaluates the opinion of the caregiver about the patient's quality of life. Total score ranges from 13 to 52. Higher scores represent a better outcome. (NCT00814658)
Timeframe: Baseline, Week 8, Week 24

Interventionscores on a scale (Mean)
Galantamine + Nimodipine (Baseline)28.33
Galantamine + Placebo (Baseline)29.33
Galantamine + Nimodipine (Week 8)27.80
Galantamine + Placebo (Week 8)29.78
Galantamine + Nimodipine (Week 24)29.80
Galantamine + Placebo (Week 24)29.13

The Clinical Global Impression (CGI) at Week 4, Week 8, Week 16, and Week 24

The Clinical Global Impression (CGI) is a scale to assess treatment response in patients with mental disorders. The Clinical Global Impression Improvement scale (CGI-I) requires the clinician to rate how much the patient's illness has improved or worsened relative to a baseline state. A patient's illness is compared to change over time and rated as: very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse. (NCT00814658)
Timeframe: Week 4, Week 8, Week 16, Week 24

,,,,,,,
Interventionparticipants (Number)
Very much improvedMuch improvedMinimally improvedNo changeMinimally worseMuch worseVery much worse
Galantamine + Nimodipine (Week 16)0121100
Galantamine + Nimodipine (Week 24)0131000
Galantamine + Nimodipine (Week 4)0114100
Galantamine + Nimodipine (Week 8)0022100
Galantamine + Placebo (Week 16)0035000
Galantamine + Placebo (Week 24)0241100
Galantamine + Placebo (Week 4)0154000
Galantamine + Placebo (Week 8)0162000

Reviews

5 reviews available for nimodipine and Dementia

ArticleYear
[The importance of nimodipine in treatment of dementia].
    Pharmazie in unserer Zeit, 2005, Volume: 34, Issue:5

    Topics: Alzheimer Disease; Animals; Calcium Channel Blockers; Calcium Signaling; Dementia; Dementia, Vascula

2005
[Altered calcium homeostasis in brain aging and senile dementia, new approach to treat Alzheimer's disease].
    Yao xue xue bao = Acta pharmaceutica Sinica, 1993, Volume: 28, Issue:9

    Topics: Aging; Animals; Brain; Calcium; Calcium Channel Blockers; Calcium Channels; Dementia; Humans; Learni

1993
New treatments for dementia. Myth, magic, and science.
    Canadian family physician Medecin de famille canadien, 1994, Volume: 40

    Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Attitude to Death; Attitude to Health; Canada; Cult

1994
[Therapy of dementing diseases: value of calcium antagonists].
    Fortschritte der Medizin, 1993, Oct-10, Volume: 111, Issue:28

    Topics: Aged; Brain; Calcium Channel Blockers; Calcium Channels; Clinical Trials as Topic; Dementia; Humans;

1993
[Piracetam, nimodipine and tacrine in the pharmacologic treatment of dementia: bibliographic review].
    Atencion primaria, 1996, Sep-30, Volume: 18, Issue:5

    Topics: Aged; Aged, 80 and over; Dementia; Double-Blind Method; Humans; Nimodipine; Nootropic Agents; Pirace

1996

Trials

5 trials available for nimodipine and Dementia

ArticleYear
Effects of galantamine and galantamine combined with nimodipine on cognitive speed and quality of life in mixed dementia: a 24-week, randomized, placebo-controlled exploratory trial (the REMIX study).
    Arquivos de neuro-psiquiatria, 2014, Volume: 72, Issue:6

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cerebrovascular Disorders; Cholinesterase Inhibitors; Co

2014
Divergent neuroprotective effects of nimodipine in PDD and MID provide indirect evidence of disturbances in Ca2+ homeostasis in dementia.
    Methods and findings in experimental and clinical pharmacology, 1993, Volume: 15, Issue:8

    Topics: Aged; Aged, 80 and over; Aging; Calcium; Cognition; Dementia; Dementia, Multi-Infarct; Double-Blind

1993
[Brain aging and calcium antagonist drugs. A preliminary open study with nimodipine].
    La Clinica terapeutica, 1992, Volume: 140, Issue:1

    Topics: Aged; Aged, 80 and over; Aging; Brain; Dementia; Drug Tolerance; Female; Humans; Male; Nimodipine; P

1992
Efficacy and clinical relevance of cognition enhancers.
    Alzheimer disease and associated disorders, 1991, Volume: 5 Suppl 1

    Topics: Acetylcarnitine; Clinical Trials as Topic; Cognition; Cognition Disorders; Dementia; Humans; Nimodip

1991
Nimodipine in the treatment of old age dementias.
    Progress in neuro-psychopharmacology & biological psychiatry, 1990, Volume: 14, Issue:4

    Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Blood Pressure; Dementia; Double-Blind Method; El

1990

Other Studies

3 other studies available for nimodipine and Dementia

ArticleYear
Neuropharmacology of nimodipine: from single channels to behavior.
    Annals of the New York Academy of Sciences, 1994, Dec-15, Volume: 747

    Topics: Aging; Amyloid beta-Peptides; Animals; Behavior, Animal; Calcium; Cells, Cultured; Dementia; Female;

1994
Prescribing practice with cognition enhancers in outpatient care: are there differences regarding type of dementia?--Results of a representative survey in lower Saxony, Germany.
    Pharmacopsychiatry, 1996, Volume: 29, Issue:4

    Topics: Adult; Alzheimer Disease; Ambulatory Care; Data Collection; Dementia; Dementia, Vascular; Female; Ge

1996
[Effectiveness and tolerance of nimodipine in long-term treatment of patients with organic brain disorders].
    Zeitschrift fur arztliche Fortbildung, 1992, May-11, Volume: 86, Issue:9

    Topics: Aged; Dementia; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Long

1992